ClinicalTrials.gg
Not yet recruitingNCT07240987Updated Nov 16, 2026

Mesenchymal Stem Cells for Chronic Kidney Diseases

A Phase 1/2 interventional study of 0.9% sodium chloride and MSCs in Kidney Disease, Chronic, Diabetic Kidney Disease (DKD) and Hypertensive Nephropathy, sponsored by The First Affiliated Hospital of Air Force Medical University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by The First Affiliated Hospital of Air Force Medical University · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Start date movedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the effect of intravenous injection of umbilical cord tissue derived mesenchymal stem cells (UMSCs) on the improvement of renal function in patients with chronic kidney disease (CKD) at stage 3 or 4, with the change of estimated glomerular filtration rate (eGFR) as the primary endpoint, and other changes in renal function laboratory indicators, changes in other organ system function laboratory indicators, and adverse reaction events as secondary endpoints. This trial aims to further evaluate the efficacy and safety of UMCSs in CKD patients, and provide new insights into expanding the clinical treatment strategies, delaying the progression and improving the prognosis of CKD patients.

02

Conditions studied

  • Kidney Disease, Chronic
  • Diabetic Kidney Disease (DKD)
  • Hypertensive Nephropathy
03

In context

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

This study's planned enrollment of 32 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

This is the only study on the registry with The First Affiliated Hospital of Air Force Medical University as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agreement to participate in the trial and provision of signed written
  • Pathological diagnosis of diabetic nephropathy or hypertensive renal damage
  • 15 ≤ \< 60 mL/min/1.73m², UACR > 300 mg/g
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • Extremely severe anemia ( \< 30 g/L)
  • Received blood product transfusion therapy within 1 month
  • Autosomal dominant or recessive polycystic kidney disease (ADPKD)
  • History of kidney transplant or other solid organ transplant
  • Active systemic or localized infection (e.g., pneumonia, osteomyelitis)
  • Allergy to stem cells themselves or stem cell-related culture medium
  • History of allergic reaction to cell products (e.g., blood transfusion, )
  • History of coagulation disorders (thromboembolism, pulmonary embolism, deep vein thrombosis)
  • History of or current malignant disease
  • Elevated tumor markers (AFP, CEA, CA199, CA125, etc.)
  • Pregnant women or women with plans for pregnancy within 3 months after MSC therapy
  • Participation in drug-related clinical trials within the past 2 months
  • Any form of drug abuse, mental illness, or other conditions considered by the investigator as potentially affecting the trial's validity or the subject's health
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    DKD

    Drug: MSCs

  • Experimental
    HN

    Drug: MSCs

  • Placebo comparator
    non-DKD

    Drug: 0.9% sodium chloride

  • Placebo comparator
    non-HN

    Drug: 0.9% sodium chloride

Interventions

  • Drug0.9% sodium chloride

    The control group will receive a placebo, which is an intravenous infusion of 250 mL of 0.9% sodium chloride injection.

  • DrugMSCs

    The experimental group will receive an intravenous injection of allogeneic MSCs at a dose of 1.0×10⁶ cells per kilogram, reconstituted with 250 mL of sodium chloride injection.

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    Efficacy Endpoints: Changes in eGFR, 24-hour urine protein, and UACR at 1, 3, 6, and 12 months will serve as primary endpoints to assess renal function improvement. Changes in other renal function parameters (e.g., quantitative urine protein, urine red blood cells, serum creatinine, cystatin C),and changes in other organ system function parameters (e.g., ECG/echocardiography, complete blood count, liver function, NT-proBNP, parathyroid hormone, 25-dihydroxyvitamin D, lymphocyte subsets) at 1, 3, 6, and 12 months will serve as secondary endpoints.

    Time frame: From enrollment to the end of treatment at 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 22 phase 1/2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 9 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartEst.
Nov 1, 2026was Jan 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 1, 2026→Nov 1, 2026
Nov 16, 2026
Sponsor
The First Affiliated Hospital of Air Force Medicial University→The First Affiliated Hospital of Air Force Medical University
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Jan 1, 2026→Nov 1, 2026
    Sponsor The First Affiliated Hospital of Air Force Medicial University→The First Affiliated Hospital of Air Force Medical University
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07240987
Lead sponsor
The First Affiliated Hospital of Air Force Medical University
Responsible party
Li Jipeng (Principal Investigator, The First Affiliated Hospital of Air Force Medical University) — Principal investigator
First posted
Nov 21, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion